Aiming to be ‘European anchor’ in expansion rounds, Kurma raises €160M toward growth fund

Kurma Partners believes its new Growth Opportunities fund can fill a niche by investing in maturing European life sciences companies that aren’t yet ready to test the public markets, including biopharmas around the proof-of-concept stage.

Kurma said Monday it had raised €160 million ($173.8 million) in the fund’s first close, with a €250 million target for a final close. The vehicle will complement Kurma’s core series of Biofunds including the current 2020-vintage, €160 million Biofund III, with which it emphasizes company creation...